Heavy Ion Therapy System segmentation by type classifies installations according to accelerator architecture, beam‑delivery modality, and ion species, each factor affecting cost structure and adoption rate. The most prevalent accelerator is the synchrotron, responsible for roughly 60 % of deployed systems; its variable energy extraction enables precise range modulation across multiple ion species, making it the preferred choice for high‑volume cancer centers. Cyclotron‑based units, comprising about 30 % of the market, offer a more compact footprint and continuous beam output but are limited to fixed energies, requiring additional energy‑degrading hardware that can increase secondary radiation. Emerging laser‑accelerated prototypes, still under 10 % adoption, promise ultra‑compact designs and reduced infrastructure costs, yet they face challenges in beam stability and regulatory approval. Within each accelerator class, delivery methods—passive scattering versus active scanning—further differentiate product lines, with active scanning increasingly favored for its superior conformality. Finally, ion species such as carbon, oxygen, and neon dictate biological effectiveness; carbon ions dominate due to a well‑established clinical evidence base, while oxygen and neon remain niche, primarily in research settings. This taxonomy clarifies how each type contributes to total market volume.
